NKTR 8-K: SEC filing

Nektar Therapeutics

Filed with the SEC on Nov 12, 2026 · accession 0001213900-26-118964

NKTR filed a 8-K (current report) with the SEC on Nov 12, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Nektar Therapeutics issued a press release announcing its financial results for the quarter ended September 30, 2026, furnished as Exhibit 99.1 to this Form 8-K.

For details, click here →How to read a 8-K →

Key details

RegistrantNektar Therapeutics

Vice president, legalElizabeth Zhang

✦ Ask GOAX AI about this filing — what it means for NKTR, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for NKTR?

Click here

Frequently asked questions

What did NKTR file with the SEC on Nov 12, 2026?

NKTR filed a 8-K (SEC filing). Nektar Therapeutics issued a press release announcing its financial results for the quarter ended September 30, 2026, furnished as Exhibit 99.1 to this Form 8-K.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other NKTR SEC filings

Get alerts when NKTR files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

NKTR overview NKTR analysis NKTR news Latest SEC filings